scholarly journals Spontaneous regression of plasmablastic lymphoma in an elderly human immunodeficiency virus (HIV)-negative patient

2015 ◽  
Vol 10 (1) ◽  
Author(s):  
Takuro Igawa ◽  
Yasuharu Sato ◽  
Hotaka Kawai ◽  
Eisei Kondo ◽  
Mai Takeuchi ◽  
...  
2021 ◽  
Vol 84 (4) ◽  
pp. 659-661
Author(s):  
L Bricman ◽  
P Yengue ◽  
C Miscu ◽  
S Junius ◽  
F Waignein ◽  
...  

Plasmablastic lymphoma (PBL) represents a rare and aggressive subtype of diffuse large B cells lymphoma (DLBCL) most associated with the human immunodeficiency virus (HIV). Prognosis remains poor despite various treatment approaches. We describe an evolution at six months of HIV negative PBL and Ebstein Barr virus (EBV) positive PBL with chemotherapy. Role of radiotherapy is still unclear.


2003 ◽  
Vol 82 (8) ◽  
pp. 521-525 ◽  
Author(s):  
D. D. Nguyen ◽  
B. W. Loo ◽  
G. Tillman ◽  
Y. Natkunam ◽  
T. M. Cao ◽  
...  

2011 ◽  
Vol 35 (12) ◽  
pp. 1571-1577 ◽  
Author(s):  
Jane Jijun Liu ◽  
Ling Zhang ◽  
Ernesto Ayala ◽  
Teresa Field ◽  
Jose L. Ochoa-Bayona ◽  
...  

2021 ◽  
Vol 9 ◽  
pp. 232470962110174
Author(s):  
Kemnasom Nwanwene ◽  
Noman Ahmed Jang Khan ◽  
Mohamed Alsharedi

Plasmablastic lymphoma (PBL) is a very rare disease and it is usually considered a human immunodeficiency virus (HIV)–related B-cell lymphoma that carries a poor prognosis. It mostly involves the oral cavity, lungs, nasal cavity, gastrointestinal tract, lymph node, and skin. Therapeutic regimens like dose-adjusted etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone (DA-EPOCH) have shown better results in these aggressive lymphomas. We report a rare case of PBL in an HIV-negative patient who presented to the clinic with a complaint of left testicular swelling for 3 months. Ultrasound showed an enlarged left testicle. He underwent a left orchiectomy and the pathology showed PBL with involvement of the spermatic cord margin. Positron emission tomography scan showed hypermetabolic mediastinal and hilar lymph nodes. He was started on DA-EPOCH but showed no response. Accordingly, salvage therapy with bortezomib in addition to ifosfamide carboplatin and etoposide (B-ICE) chemotherapy was initiated with remarkable response. Several other regimens can be used in the refractory setting; however, the evidence is mostly based on retrospective analysis.


Sign in / Sign up

Export Citation Format

Share Document